Ivermectin And Pyrantel Pamoate

The core mechanism of Ivermectin is to activate invertebrate GluCls, leading to chloride ion influx and causing neuromuscular hyperpolarization. However, although mammals lack GluCls in their bodies, drugs may produce non targeted effects through the following pathways:

GABA receptor cross reactivity: High doses of Ivermectin can enhance the activity of gamma aminobutyric acid (GABA) receptors in mammals, affecting central nervous system function. Research has shown that Collies have P-glycoprotein (P-gp) defects due to MDR1 gene mutations, which prevent effective excretion of Ivermectin from the brain and can lead to neurotoxicity such as ataxia and tremors.
Mitochondrial dysfunction: In vitro experiments have shown that Ivermectin can induce DNA double strand breaks in human cervical cancer cells (HeLa) and activate autophagy through the AMPK/mTOR pathway, suggesting its potential genotoxicity to eukaryotic cells.
Environmental persistence: Ivermectin residues in animal excrement can persist in soil and water for a long time, posing a chronic exposure risk to non targeted organisms such as earthworms and aquatic invertebrates.

Pyrantel Pamoate induces muscle spastic paralysis by stimulating the parasite nAChR, but its effects on non targeted organisms are mainly reflected in:

Mammalian nAChR cross reactivity: Although there are structural differences between mammalian muscle nAChR and parasite receptors, high-dose Pyrantel may cause skeletal muscle overstimulation, leading to muscle weakness or respiratory depression.
Microbial community disturbance: Pyrantel residues in soil may inhibit the activity of nitrifying bacteria and affect nitrogen cycling processes.
Spread of drug resistance genes: Long term low-dose exposure may drive mutations in the nAChR gene of parasites, leading to the development of drug resistance and indirectly affecting ecological balance.

Exposure effect threshold: Establish a non targeted biological dose-response curve to determine the No Observed Effect Concentration (NOEC). For example, Ivermectin has a NOEC of 0.05mg/kg for earthworms.
Ecological risk index: Combining drug environmental persistence (DT50), bioaccumulation (BCF), and toxicity (EC50), calculate the environmental risk quotient (RQ). When RQ>1, control measures need to be activated.
Sensitivity grading: Develop differentiated medication guidelines for different species (such as Collies vs. regular dogs).

Precision medication technology: Developing weight/breed specific dosing regimens, such as screening MDR1 mutant dogs through genetic testing.
Environmental remediation technology: using ozone oxidation or microbial degradation to reduce drug residues.
Alternative therapy development: Explore natural products (such as Melia azedarach extract) or gene editing techniques (such as RNA interference) to reduce the use of chemical drugs.

Residue limit standard: Establish the maximum residue limit (MRL) for Ivermectin in animal derived foods, such as the EU regulation of 10 μ g/kg for beef.
Environmental emission control: It is required that breeding farms carry out harmless treatment of medicated feces and prohibit direct discharge into water bodies.
Drug resistance monitoring network: Establish a global parasite drug resistance database to guide clinical medication strategy adjustments.